Replies to post #209460 on NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

photonic5,

I do believe that cost has been a factor but patent protection and optimization while they wait on DCVax-L is absolutely key. If this small trial was really going to be sponsored significantly then any cost to NWBO should have been minimal. If they know it will be working to actually kill tumors after 8-12 weeks in an established patient group (patent claim) then the results would speak for themselves in very short order especially with treatment spacings tightened and this should reduce costs even more. Best wishes.

[flipper44]

Starting a new more aggressive trial in the brain with Direct probably ends up instead being delayed until phase III DCVax-L trial is complete. I expect IRIS in the Direct brain metastases trial (aka: likely very safe but complicated to educate the regulators/public), and they probably don't need that complex dynamic prior to resolving this very safe DCVax-L trial. That's where I'm at right now. Hoping topline is very soon so that we can move forward with (hopefully) L's BLA, and, fingers crossed, Direct and L trials in additional indications.